Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 144,756 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 144,756 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the completion of the sale, the insider directly owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. This represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total value of $6,426,655.83.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The stock was sold at an average price of $37.30, for a total value of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Down 1.5%

Shares of NASDAQ ROIV traded down $0.54 during trading on Friday, reaching $36.30. The company had a trading volume of 6,185,493 shares, compared to its average volume of 5,631,176. The stock has a market cap of $26.22 billion, a P/E ratio of -68.49 and a beta of 1.12. The company’s fifty day moving average price is $34.61 and its 200-day moving average price is $30.43. Roivant Sciences Ltd. has a 12 month low of $11.60 and a 12 month high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, equities analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ROIV shares. HC Wainwright raised their price target on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday. Citigroup increased their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Guggenheim lifted their target price on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.14.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. UBS Group AG increased its stake in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares in the last quarter. Morgan Stanley lifted its position in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. boosted its stake in Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Norges Bank bought a new position in Roivant Sciences during the fourth quarter worth $112,750,000. Finally, Jefferies Financial Group Inc. acquired a new stake in Roivant Sciences in the fourth quarter worth $76,272,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.